Monthly versus quarterly fremanezumab for the prevention of migraine: a systemic review and meta-analysis from randomize
- PDF / 536,988 Bytes
- 10 Pages / 595.276 x 790.866 pts Page_size
- 98 Downloads / 172 Views
ORIGINAL ARTICLE
Monthly versus quarterly fremanezumab for the prevention of migraine: a systemic review and meta-analysis from randomized controlled trials Bixi Gao 1 & Qiran Lu 2 & Rong Wan 3 & Zilan Wang 1 & Yanbo Yang 1 & Zhouqing Chen 1 & Zhong Wang 1 Received: 4 August 2020 / Accepted: 22 October 2020 # Springer-Verlag GmbH Germany, part of Springer Nature 2020
Abstract Fremanezumab (TEV-48125) is a novel therapeutic drug for migraine prevention. Previous randomized controlled trials have proved the efficacy of fremanezumab; however, no systematic review has been performed to compare the differences between monthly and quarterly administration of fremanezumab. This meta-analysis aims to probe into the safety and efficacy of monthly fremanezumab for the prevention of migraine versus quarterly fremanezumab. We searched Pubmed, Embased, and Cochrane Library from December 1999 to December 2019 for randomized controlled trials (RCTs). Our meta-analysis finally pooled three RCTs with 1884 patients. We combined 1884 patients from three randomized controlled trials; the primary endpoint was mean monthly migraine days, from baseline to week 12. We concluded that the monthly administration of fremanezumab brought about a significant reduction in migraine days versus quarterly fremanezumab (P = 0.0008). Besides, monthly and quarterly fremanezumab have the same risk with mild and severe adverse events (P = 0.50; P = 0.39). Monthly administration of fremanezumab shows better outcomes for preventing migraines than quarterly fremanezumab and will not let to more adverse events. Patients with episodic migraine (EM) benefit more from monthly fremanezumab than patients with chronic migraine (CM). Keywords Fremanezumab . Monthly administration . Quarterly administration . Chronic migraine . Episodic migraine . Meta-analysis
Introduction Migraines affect more than 16% of people in the world. It is one of the most common neurological diseases, and its
features are frequent attacks of moderate or severe pulsating headache pain or associated symptoms (nausea, photophobia, and phonophobia) (Goadsby et al. 2017; Headache Classification Committee of the International Headache S
Bixi Gao and Qiran Lu contributed equally to this work. Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00210-02002009-7. * Zhouqing Chen [email protected]
Zilan Wang [email protected]
* Zhong Wang [email protected]
Yanbo Yang [email protected]
Bixi Gao [email protected] Qiran Lu [email protected] Rong Wan [email protected]
1
Department of Neurosurgery, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou 215006, Jiangsu Province, China
2
Department of Gastrointestinal Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215006, Jiangsu Province, China
3
Jiangsu University, Zhenjiang 212000, Jiangsu Province, China
Naunyn-Schmiedeberg's Arch Pharmacol
2013; Disease et al. 2017). People with migraine experience diminished q
Data Loading...
